As device developers of all sizes grapple with the updated transition timeline for EU MDR compliance and the recent EU AI Act approval falls short of expectations, the question looms: how can regul
Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the fie
Despite exciting advancements and new investments into the field, the development of new RNAi therapeutics is plagued by difficulties with extra-hepatic delivery and scale-up of manufacturi
Reuniting metabolic experts to enable the assessment of the competitive landscape, the 7th Obesity & NASH Drug Development Summit is your exclusive industry meeting to:
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.